U.S. markets close in 4 hours 30 minutes
  • S&P 500

    4,400.38
    +46.19 (+1.06%)
     
  • Dow 30

    34,313.92
    +394.08 (+1.16%)
     
  • Nasdaq

    14,882.73
    +136.33 (+0.92%)
     
  • Russell 2000

    2,219.11
    +32.92 (+1.51%)
     
  • Crude Oil

    71.41
    +0.92 (+1.31%)
     
  • Gold

    1,778.90
    +0.70 (+0.04%)
     
  • Silver

    22.92
    +0.31 (+1.39%)
     
  • EUR/USD

    1.1741
    +0.0011 (+0.09%)
     
  • 10-Yr Bond

    1.3160
    -0.0080 (-0.60%)
     
  • GBP/USD

    1.3660
    -0.0005 (-0.03%)
     
  • USD/JPY

    109.5910
    +0.3710 (+0.34%)
     
  • BTC-USD

    42,722.76
    +37.05 (+0.09%)
     
  • CMC Crypto 200

    1,066.02
    +25.54 (+2.45%)
     
  • FTSE 100

    7,088.20
    +107.22 (+1.54%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

This Drug's New Indication in China Will Be a Boost to AstraZeneca

·4 min read
This Drug's New Indication in China Will Be a Boost to AstraZeneca
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

On July 19, AstraZeneca (NASDAQ: AZN) announced that it had received approval from China's National Medical Products Administration (NMPA) for its drug Imfinzi. This followed the NMPA's review of positive results from a phase 3 trial. Imfinzi can now be used as a first-line treatment for adults with extensive-stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy.